A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen ( TAM ) to combination chemotherapy with perioperative mitomycin C ( MMC ) and ftorafur ( FT ) for patients with estrogen receptor ( ER ) - positive tumors and the addition of PSK , a biologic response modifier , to MMC+FT chemotherapy for patients with ER-negative tumors in operable Stage IIA , IIB , and IIIA cancer .
